LIGAND PHARM Performance

LGNZZ -- USA Stock  

USD 0.08  0.01  11.11%

LIGAND PHARM holds performance score of 4 on a scale of zero to a hundred. The company secures Beta (Market Risk) of 5.5944 which conveys that as market goes up, the company is expected to significantly outperform it. However, if the market returns are negative, LIGAND PHARM will likely underperform.. Although it is vital to follow to LIGAND PHARM INC price patterns, it is good to be conservative about what you can actually do with the information regarding equity historical price patterns. Macroaxis philosophy towards estimating future performance of any stock is to look not only at its past charts but also at the business as a whole, including all fundamental and technical indicators. To evaluate if LIGAND PHARM expected return of 1.1389 will be sustainable into the future, we have found twenty-one different technical indicators which can help you to check if the expected returns are sustainable. Use LIGAND PHARM INC Standard Deviation, Value At Risk, Kurtosis, as well as the relationship between Jensen Alpha and Semi Variance to analyze future returns on LIGAND PHARM INC.
Horizon     30 Days    Login   to change

LIGAND PHARM INC Relative Risk vs. Return Landscape

If you would invest  8.00  in LIGAND PHARM INC on August 24, 2018 and sell it today you would earn a total of  0.00  from holding LIGAND PHARM INC or generate 0.0% return on investment over 30 days. LIGAND PHARM INC is currently producing 1.1389% returns and takes up 18.3849% volatility of returns over 30 trading days. Put another way, most equities are less risky on the bases of their return distribution than the company and majority of traded equity instruments are likely to generate higher returns over the next 30 trading days.
 Daily Expected Return (%) 
      Risk (%) 
Assuming 30 trading days horizon, LIGAND PHARM INC is expected to generate 40.97 times more return on investment than the market. However, the company is 40.97 times more volatile than its market benchmark. It trades about 0.06 of its potential returns per unit of risk. The DOW is currently generating roughly 0.39 per unit of risk.

LIGAND PHARM Market Risk Analysis

Sharpe Ratio = 0.0619
Best
Portfolio
Best
Equity
Good Returns
Average Returns
Small ReturnsLGNZZ
CashSmall
Risk
Average
Risk
High
Risk
Huge
Risk
Negative Returns

LIGAND PHARM Relative Performance Indicators

Estimated Market Risk
 18.38
  actual daily
 
 4 %
of total potential
  
Expected Return
 1.14
  actual daily
 
 21 %
of total potential
  
Risk-Adjusted Return
 0.06
  actual daily
 
 4 %
of total potential
  
Based on monthly moving average LIGAND PHARM is performing at about 4% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of LIGAND PHARM by adding it to a well-diversified portfolio.

LIGAND PHARM Performance Rating

LIGAND PHARM INC Risk Adjusted Performance Analysis

4 

Risk-Adjusted Performance

Compared to the overall equity markets, risk-adjusted returns on investments in LIGAND PHARM INC are ranked lower than 4 (%) of all global equities and portfolios over the last 30 days.

LIGAND PHARM Alerts

Equity Alerts and Improvement Suggestions

LIGAND PHARM INC appears to be very risky and stock price may revert if volatility continues
LIGAND PHARM INC has some characteristics of a very speculative penny stock
Latest headline from www.gurufocus.com: Moody Aldrich Partners Llc Buys Amedisys Inc, Ligand Pharmaceuticals Inc, Calavo Growers Inc, Sells Wintrust ...
Please see also Stocks Correlation. Please also try Companies Directory module to evaluate performance of over 100,000 stocks, funds, and etfs against different fundamentals.
Search macroaxis.com